Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
(2011) New England Journal of Medicine — Vol. 364, n° 6, p. 501-513 (2011)
Files
No attached file found for this publication.
Details
- Authors
- et. al.
- Abstract
- The multitargeted tyrosine kinase inhibitor sunitinib has shown activity against pancreatic neuroendocrine tumors in preclinical models and phase 1 and 2 trials.
- Affiliations
Citations
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., Chen, J.-S., Hörsch, D., Hammel, P., Wiedenmann, B., Van Cutsem, E., Patyna, S., Lu, D. R., Blanckmeister, C., Chao, R., et al. (2011). Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New England Journal of Medicine, 364(6), 501-513. https://doi.org/10.1056/NEJMoa1003825 (Original work published 2011)